Ovarian Cancer Clinical Trial

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Summary

The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling).

View Full Description

Full Description

This research study is a randomized controlled trial that will compare an exercise group to a control group on lower extremity function, CIPN, and inflammatory markers in ovarian or endometrial cancer patients undergoing first-line chemotherapy after surgery.

The names of the study interventions involved in this study are/is:

Aerobic and resistance exercise; virtually supervised 16-week aerobic and resistance exercise performed at home via Zoom
Attention control for 16 weeks, home-based stretching

The research study procedures include: screening for eligibility and study interventions including evaluations and follow up visits.

It is expected that about 30 people will take part in this research study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Newly diagnosed patients with stages III-IV ovarian or endometrial cancer
Receiving first-line carboplatin and paclitaxel chemotherapy after surgery
≥18 years, children under the age of 18 will be excluded due to rarity of disease
Physician's clearance to participate in moderate-vigorous intensity exercise
Able to read, write, and understand English
Ability to understand and the willingness to sign an informed consent document
Willing to undergo two venous blood draws for the study

Exclusion Criteria:

Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist
Participants with uncontrolled intercurrent illness, as determined by the treating oncologist
Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating oncologist
Participants who have received prior chemotherapy for cancer treatment (e.g. taxanes for breast cancer)

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

30

Study ID:

NCT04997096

Recruitment Status:

Recruiting

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Christina Dieli-Conwright, PhD, MPH
Contact
617-582-8321
[email protected]
Mary Norris, MS
Contact
857-215-0195
[email protected]
Christina Dieli-Conwright, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

30

Study ID:

NCT04997096

Recruitment Status:

Recruiting

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.